Dipeptidyl peptidase-4 (DPP-4), a serine protease, degrades peptides containing alanine or proline residues and amino-terminal residues of proteins.
It is an aminopeptidase found in most tissues of the body, including the liver, lung, kidney, intestine, lymph nodes, and endothelial cells, and resides on cell membranes, where it exerts its effect. Physiological effects of DPP-4 can be broadly divided into enzymatic effects such as the inhibition of incretins and non-enzymatic effects associated with immune regulation, behavioral response, and inflammation depending on the substance on which DPP-4 acts.
2,3 Since Lamers et al. 4 reported DPP-4 as novel adipokine, many studies have shown serum DPP-4 level or activity to be associated with obesity, diabetes mellitus, and fatty liver. 5, 6 Our previous study showed serum DPP-4 concentration was positively correlated with lean body mass, total cholesterol, and creatinine and was elevated in the obese group compared to the normal weight group, as reported in Journal of Obesity & Metabolic Syndrome. 7 It is an honor to reply to a Letter to the Editor with great comments on our study.
Thus, we kindly respond to the issues raised in the Letter.
Our studies evaluated whether serum DPP-4 concentration is associated with obesity and obesity-related factors such as glucose, lipid profile, and body fat using blood test and bio-impedance analysis. Even though our study showed that serum DPP-4 level was higher in the obese group, these studies indirectly re- 
